ARJUNA Therapeutics announces the appointment of Martin Treder, PhD as Chief Scientific Officer
Officer. He will lead the development of ARJUNA's lead assets into clinical development and
advance the broad pipeline of TMC compounds. Dr. Treder was most recently CSO and
Managing Director of Affimed (NASQ: AFMD) where he led research and development of its
proprietary fit-for-purpose innovative platform in hematology and solid tumors.
Ross Breckenridge MD PhD, CEO of ARJUNA said, "We are delighted to have someone of
Martin's high calibre and deep experience joining our team to lead our R+D efforts. This is a
huge step forward for our company and will accelerate our progress towards the clinic".
Dr. Treder has 19 years of professional experience in oncology research and development,
being responsible for establishing and driving innovative preclinical programmes. He co-
founded and served as CSO for CT Atlantic in Zurich, Switzerland, and co-founded U3
Pharma AG in Munich, Germany (acquired by Daiichi Sankyo).
Dr. Treder commented, "I am looking forward to join the team at Arjuna and excited to
drive the development of these innovative and potentially transformative therapies in order
to make them available for underserved patients and those who have run out of treatment
ARJUNA Therapeutics is developing an entirely novel platform of orally available small
molecules to address the unmet needs in cancer medicine. The first molecule in ARJUNA's
pipeline is a pan-tumour targeted therapy that crosses the blood-brain-
tumours with mitochondrial dysfunction - a very large group of untreatable cancers that
contains KRAS mutation driven tumours and glioblastoma multiforme.
For more information, visit our website: